Next-generation Cancer Models
As part of our pledge to elevate biological models, ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2D and 3D patient-derived in vitro cancer models, including organoids. ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.
Cancer Models Based on Physiological System:
What Are Organoids
Organoids are complex, self-organizing microtissues grown embedded within 3D extracellular matrix. Organoids may contain multiple differentiated cell types, exhibit cellular polarization, and often possess a central lumen and other in vivo–like architectural features. Organoids are capable of long-term expansion in culture while remaining phenotypically and genetically stable. Primary patient-derived organoids have been described for various tissues, healthy and cancerous, including colon, intestine, stomach, breast, esophagus, lung, liver, prostate, and pancreas. Organoids are invaluable pre-clinical models for studying cancer and offer many advantages over existing human or non-human animal cancer models.
Check out our HCMI Resources to learn more about these and other next-generation models.
Back to top
Advanced Biological Models
Advanced culture technologies such as three dimensional organoids and conditional reprograming of cells permit the generation and propagation of cancer models that are better able to recapitulate the complexity of human tumors compared with existing cell lines, lending further credibility to your research. To enhance their clinical relevance, HCMI models have been annotated with clinical and bioinformatics data, which will be made available to the research community.
Back to top
- Various types of 2D and 3D patient-derived models
- All models are human-patient derived
- Diverse genetic backgrounds
- Model-specific, easy-to-follow culturing protocols
- Clinical and sequencing data available
- Models from primary, metastatic, and recurrent cancer
- Rare and pediatric cancers included
- Advanced models such as organoids and CRCs
What is the Early Adopter Program?
Don't see the next-generation in vitro model that you need for your experiments? Follow the link below to apply for early access to organoids, conditionally reprogrammed cells, and other novel models for cancer research.
Back to top
Human Cancer Models Initiative (HCMI)
HCMI is an international consortium that is dedicated to generating novel human tumor-derived culture models with associated genomic and clinical data. The HCMI consortium comprises funding agencies and cancer model development institutions. The consortium's funding agencies include the National Cancer Institute (NCI), Cancer Research UK (CRUK), Hubrecht Organoid Technology (HUB), and Wellcome Sanger Institute (WSI). NCI-funded model development institutions include the Broad Institute and the Cold Spring Harbor Laboratory. CRUK and WSI co-fund organoid development in the United Kingdom; CRUK provides the patient samples, while WSI derives and sequences the organoid models. The foundation HUB is a Netherlands-based not-for-profit organization that derives and sequences organoid models. ATCC was selected as the sole distributor for the HCMI models. The generating institutions deposit the models into ATCC, where they are authenticated, expanded, preserved, and made available for global distribution. The HCMI model data is available from the NCI as a resource to the research community.
Back to top